{{Rsnum
|rsid=1128870
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Chromosome=6
|Orientation=plus
|Gene=SLC29A1
|position=44230578
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=SLC29A1
}}{{PharmGKB
|RSID=rs1128870
|Name_s=SLC29A1:778G>A, 66G>A, mRNA 1091/932/929/841/734G>A, E200E
|Gene_s=SLC29A1
|Feature=Exon
|Evidence=PubMed ID:15224082
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Variants identified in a screen of 13 genes involved in the gemcitabine drug metabolic pathway. For the synonymous SLC29A1:778G>A (E200E) SNP, the A allele was not observed among the Europeans and Africans interrogated in this study. There was no significant difference between ethnic groups in genotype frequency distribution (p > 0.05). Study size: 181. Study population/ethnicity: Healthy, unrelated blood donors of European (n = 95) and African (n = 86) descent. Significance metric(s): Not significant, p > 0.05. Type of association: GN.
|Drugs=gemcitabine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110724
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}